Skip to main content
. Author manuscript; available in PMC: 2014 Feb 21.
Published in final edited form as: Chem Biol. 2013 Feb 21;20(2):188–201. doi: 10.1016/j.chembiol.2012.11.010

Figure 4. RvD3 is a potent anti-neutrophil and cytokine regulator.

Figure 4

RvD3, AT-RvD3 (10 ng/mouse) or vehicle (saline containing 0.1% EtOH) was administered i.v. 10 min prior to i.p. injection of zymosan (1mg/mouse). Exudates were collected 4 h later. (A) Cells were enumerated and PMN identified using flow cytometry. (B) IL-6 and (C) IL-10 levels were measured in peritoneal exudates. Results are mean ± SEM, n = 4 mice per group. * p <0.05 and *** p <0.001 vs. zymosan plus vehicle. Dorsal skin inflammation (see Experimental Procedures): Mice were injected on Day 6 with mrTNF-α (100 ng/mouse) following administration of RvD3, AT-RvD3 (10 ng) or vehicle (saline containing 0.1% EtOH) by intrapouch injection, and at 4h lavages obtained. (D) PMN by flow cytometry. Levels of (E) MCP-1, (F) IL-6 and (G) KC. Results are mean ± SEM, n = 4 mice per group. * p <0.05; ** p <0.01 vs. TNF-α plus vehicle.